CO6511276A2 - Composición probiótica para uso en el tratamiento de la inflamación del intestino - Google Patents

Composición probiótica para uso en el tratamiento de la inflamación del intestino

Info

Publication number
CO6511276A2
CO6511276A2 CO12125095A CO12125095A CO6511276A2 CO 6511276 A2 CO6511276 A2 CO 6511276A2 CO 12125095 A CO12125095 A CO 12125095A CO 12125095 A CO12125095 A CO 12125095A CO 6511276 A2 CO6511276 A2 CO 6511276A2
Authority
CO
Colombia
Prior art keywords
treatment
intestine
inflammation
probiotic composition
cect
Prior art date
Application number
CO12125095A
Other languages
English (en)
Inventor
Mazo Jordi Espadaler
Castellana Jordi Cune
Original Assignee
Ab Biotics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Biotics Sa filed Critical Ab Biotics Sa
Publication of CO6511276A2 publication Critical patent/CO6511276A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/169—Plantarum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/41—Pediococcus
    • A23V2400/413—Acidilactici
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La composición comprende una cantidad efectiva de Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, y Pediococcus acidilactici CECT 7483. Esta composición es útil en el tratamiento de enfermedades gastrointestinales o alteraciones de la salud tales como la enfermedad inflamatoria intestinal, el síndrome del intestino irritable o la distensión y la hinchazón abdominales.
CO12125095A 2010-01-28 2012-07-25 Composición probiótica para uso en el tratamiento de la inflamación del intestino CO6511276A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29911610P 2010-01-28 2010-01-28
EP10151998 2010-01-28

Publications (1)

Publication Number Publication Date
CO6511276A2 true CO6511276A2 (es) 2012-08-31

Family

ID=42243204

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12125095A CO6511276A2 (es) 2010-01-28 2012-07-25 Composición probiótica para uso en el tratamiento de la inflamación del intestino

Country Status (18)

Country Link
US (2) US20130101566A1 (es)
EP (1) EP2528610B1 (es)
JP (1) JP5777640B2 (es)
KR (1) KR101840239B1 (es)
CN (1) CN102905712B (es)
AU (1) AU2011209407B2 (es)
BR (1) BR112012018813B1 (es)
CA (1) CA2787544C (es)
CL (1) CL2012002062A1 (es)
CO (1) CO6511276A2 (es)
ES (1) ES2437940T3 (es)
MX (1) MX2012008817A (es)
MY (1) MY162344A (es)
PL (1) PL2528610T3 (es)
RU (1) RU2563525C2 (es)
UA (1) UA109123C2 (es)
WO (1) WO2011092261A1 (es)
ZA (1) ZA201205683B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113151045A (zh) * 2011-06-10 2021-07-23 株式会社爱茉莉太平洋 分离自茶树叶的新型植物乳杆菌
US9579353B2 (en) * 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
JP5995593B2 (ja) * 2012-08-02 2016-09-21 丸善製薬株式会社 抗炎症剤
WO2014096901A1 (en) * 2012-12-18 2014-06-26 Compagnie Gervais Danone Strain of bifidobacterium animalis ssp. animalis
US20160089400A1 (en) * 2013-04-08 2016-03-31 N.V. Nutricia Fermented nutritional composition with thiol protease inhibitor
SI24570A (sl) 2013-12-23 2015-06-30 Medis D.O.O. Novi sevi rodu Lactobacillus in njihova uporaba
SG11201604840TA (en) * 2014-02-28 2016-09-29 Meiji Co Ltd Prophylactic and/or therapeutic agent for functional gastrointestinal disorders
US10967013B2 (en) * 2014-04-23 2021-04-06 National Yang-Ming University Lactic acid bacterium for prophylaxis or treatment of a stress-induced disorder and a composition containing the same
US10188684B2 (en) * 2015-04-20 2019-01-29 National Yang-Ming University Method for preventing or treating functional gastrointestinal disorder by lactic acid bacterium
ES2764210T3 (es) * 2014-11-25 2020-06-02 Dsm Ip Assets Bv Lactobacillus para usar como probiótico
BR112017011078B1 (pt) * 2014-11-28 2021-05-11 Anagenix Ip Limited usos de uma composição preparada a partir de kiwi ouro seco
US10946050B2 (en) 2015-03-16 2021-03-16 Imagilin Technology Llc Compositions comprising probiotics and methods of use thereof
US10195237B2 (en) * 2015-03-16 2019-02-05 Imagilin Technology Llc Compositions and methods for treating inflammatory related diseases or conditions using Pediococcus acidilactici probiotics
MA41010B1 (fr) * 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2017062175A1 (en) 2015-10-06 2017-04-13 Albert Einstein College Of Medicine, Inc. Microbial hyperswarmers and uses thereof
AU2018216532B2 (en) 2017-01-31 2021-06-03 Navipharm Co, Ltd Novel lactic acid bacteria and use thereof
KR102464397B1 (ko) * 2017-09-15 2022-11-08 (주)아모레퍼시픽 락토바실러스 플란타룸을 포함하는 위장관 질환의 예방 및 개선용 조성물
US11602552B2 (en) 2018-02-02 2023-03-14 Kobiolabs, Inc. Lactobacillus plantarum KBL396 strain and use thereof
CA3092354A1 (en) 2018-03-15 2019-09-19 University Of Southern California Fasting-mimicking diet (fmd) but not water-only fasting promotes reversal of inflammation and ibd pathology
KR102118343B1 (ko) * 2018-07-13 2020-06-03 롯데푸드 주식회사 장 도달력이 우수하고 장내 염증 예방 효과를 가지는 우유와 발효유
AR115757A1 (es) * 2018-07-13 2021-02-24 Cj Cheiljedang Corp Composición que comprende la cepa cjlp475 de lactobacillus plantarum y la cepa cjlp17 de lactobacillus plantarum y el uso de la misma
KR102036275B1 (ko) * 2018-10-02 2019-10-24 서울대학교 산학협력단 항-염증 활성이 우수한 페디오코커스 악시딜락티시 ldtm 5201 신균주(kctc 13563bp)
KR102038695B1 (ko) * 2018-10-30 2019-10-30 주식회사 종근당바이오 프로바이오틱스를 유효성분으로 포함하는 알코올성 장손상 예방 또는 치료용 조성물
US20220054561A1 (en) * 2018-12-14 2022-02-24 The University Of North Carolina At Chapel Hill Lachnospiraceae mitigates against radiation-induced hematopoietic/gastrointestinal injury and death, and promotes cancer control by radiation
KR102094415B1 (ko) * 2018-12-17 2020-03-30 강원대학교산학협력단 프로바이오틱 활성 및 항균활성을 갖는 페디오코커스 애시디락티시 균주
WO2021125822A1 (ko) * 2019-12-17 2021-06-24 한국 한의학 연구원 페디오코쿠스 이노피나투스를 유효성분으로 포함하는 숙취해소용 조성물
WO2022171304A1 (en) 2021-02-12 2022-08-18 Ab-Biotics, S.A. Probiotic composition for the treatment of covid-19
WO2023176849A1 (ja) * 2022-03-17 2023-09-21 株式会社カネカ グルクロニダーゼ活性剤、医薬組成物、食用組成物、及び経口用組成物
CN114921351B (zh) * 2022-05-06 2023-06-13 大连工业大学 一株具有益生功能的毕赤酵母菌dpuy-f1及在缓解结肠炎症状中的应用
CN116083277B (zh) * 2022-09-17 2024-02-13 浙江大学 具有缓解溃疡性结肠炎功效的乳酸片球菌zjuids13及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463796B (sv) 1988-03-09 1991-01-28 Carl Erik Albertsson Foerfarande foer framstaellning av en naeringskomposition och daervid framstaelld naeringskomposition
SE469875C (sv) 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
SE9501056D0 (sv) 1995-03-23 1995-03-23 Probi Ab Epithelial adherent lactobacilli
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
FR2813790B1 (fr) * 2000-09-11 2004-03-12 Dolisos Lab Preparations pharmaceutiques contenant des extraits d'isoflavone de soja et des micro-organismes probiotiques
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
EP1633378A2 (en) * 2003-06-13 2006-03-15 N.V. Nutricia Pediocin-producing pediococci
KR101095712B1 (ko) * 2003-08-21 2011-12-20 오츠카 세이야쿠 가부시키가이샤 점막 면역 부활 작용을 갖는 유산균
EP1714660A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
AT501919B1 (de) * 2005-06-14 2008-09-15 Erber Ag Probiotischer, gesundheits- bzw. leistungsfördernder futtermittel- und/oder trinkwasserzusatz für tiere sowie seine verwendung
DK1951273T3 (da) * 2005-10-06 2014-05-05 Probi Ab Anvendelse af lactobacillus til behandling af autoimmune sygdomme
US8309075B2 (en) * 2005-11-14 2012-11-13 Nutrileads Edible product containing ginseng polysaccharides and beneficial bacteria
US20070298013A1 (en) * 2006-06-23 2007-12-27 Altman Jay A Animal Nutritional Supplement and Method
JP2008013534A (ja) * 2006-07-07 2008-01-24 Health Vision:Kk ペット用プロバイオティクス製品
BRPI0909289A2 (pt) * 2008-03-14 2015-08-04 Nestec Sa Mistura simbiótica
WO2010114864A1 (en) * 2009-04-01 2010-10-07 Little Calumet Holdings, Llc Probiotic oral dosage forms
US8298526B2 (en) * 2010-06-02 2012-10-30 Genmont Biotech Inc. Lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof
WO2015021530A1 (en) * 2013-08-12 2015-02-19 Mansel Griffiths Antiviral methods and compositions comprising probiotic bacterial molecules

Also Published As

Publication number Publication date
EP2528610B1 (en) 2013-11-13
AU2011209407B2 (en) 2014-02-27
JP5777640B2 (ja) 2015-09-09
AU2011209407A1 (en) 2012-09-20
US20130101566A1 (en) 2013-04-25
KR101840239B1 (ko) 2018-03-20
WO2011092261A1 (en) 2011-08-04
RU2012136615A (ru) 2014-03-10
US20160220620A1 (en) 2016-08-04
CA2787544A1 (en) 2011-08-04
ES2437940T3 (es) 2014-01-15
BR112012018813A2 (pt) 2017-06-20
EP2528610A1 (en) 2012-12-05
MX2012008817A (es) 2012-11-23
CN102905712A (zh) 2013-01-30
MY162344A (en) 2017-06-15
CN102905712B (zh) 2015-12-16
ZA201205683B (en) 2013-08-28
US10155015B2 (en) 2018-12-18
PL2528610T3 (pl) 2014-02-28
CA2787544C (en) 2019-07-09
RU2563525C2 (ru) 2015-09-20
KR20130002372A (ko) 2013-01-08
CL2012002062A1 (es) 2013-10-04
BR112012018813B1 (pt) 2020-12-08
JP2013517784A (ja) 2013-05-20
UA109123C2 (uk) 2015-07-27

Similar Documents

Publication Publication Date Title
CO6511276A2 (es) Composición probiótica para uso en el tratamiento de la inflamación del intestino
RU2008136876A (ru) Применение bifidobacterium longum для предупреждения и лечения воспаления
WO2015047941A3 (en) Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
IL225519A0 (en) Effective preparations and methods for the treatment and diagnosis of inflammatory bowel disease
MX348611B (es) Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
MX2013003282A (es) Materiales y metodos para mejorar la funcion gastrointestinal.
HK1183620A1 (en) Compositions and their use in treating neoplasia, inflammatory disease and other disorders
EA201690147A1 (ru) Пероральные композиции
IN2012DN01638A (es)
CL2011001692A1 (es) Composicion farmaceutica que entrega acido butirico y glutamina directamente en el colon, para inducir la liberacion de una hormona intestinal desde celulas l del colon; su uso en diabetes tipo i o tipo ii y obesidad, entre otros.
CL2011001939A1 (es) Uso de lactobacillus helveticus cncm i-4095 para apoyar la perdida de peso y/o mantenimiento del peso en humanos y/o animales, particularmente para tratar la obesidad y trastornos metabólicos; y microorganismo de la cepa de lactobacillus helveticus cncm i-4095.
BRPI0906492A2 (pt) antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações
HK1221898A1 (zh) 腸易激綜合徵和炎性腸病的診斷和治療
HK1198932A1 (en) Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis -4
CL2011001937A1 (es) Uso de la cepa de lactobacillus rhamnosus cncm i-4096 para apoyar la pérdida de peso y/o mantenimiento del peso en humanos y/o animales, específicamente para el tratamiento de la obesidad.
HK1221905A1 (zh) 作爲用於炎性腸病和/或腸易激綜合征的治療的應用
ES2711427T8 (es) Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos
WO2014011564A3 (en) Compositions and method for treatment and prophylaxis of inflammatory bowel disease
ZA201105320B (en) Use of apl-type peptide for treating intestinal inflammatory diseases and type 1 diabetes
EA201291440A1 (ru) Пробиотические штаммы для применения при повышении трансэпителиального сопротивления
UA113399C2 (xx) Штам непатогенної грамнегативної бактерії та його застосування в дерматології
EP2488198A4 (en) TREATMENT AND DIAGNOSIS OF INFLAMMATORY DISORDERS
CL2009000878A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como dolor, migraña, diabetes, enfermedades del tracto respiratorio, enfermedades intestinales inflamatorias, obesidad, entre otras.
BR112012018805A2 (pt) motor
JP2014101282A5 (es)